Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Preclinical CRO Market Research Report Information By Service (Toxicology Testing, Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies), Application (Oncology, Central Nervous System (CNS) Disorders, Cardiovascular Diseases, Immunological Disorders, Respiratory Diseases, Infectious Diseases, Diabetes), End User (Pharmaceutical and Biopharmaceutical Industries, Medical Device Companies and Academic Institutes) - Forecast till 2032

ID: MRFR/HC/5807-CR | 125 Pages | Author: Kinjoll Dey| February 2021

Global Preclinical CRO Market Overview

Preclinical CRO Market is projected to record a CAGR of 7.2% to influence an earning level of USD 10.3 billion by the end of the forecast in 2032. A preclinical CRO brings the knowledge, experience, and skill essential to take a medical product or device from its clinical-stage to selling and distribution.

Preclinical CRO Market

COVID-19 Analysis With the present COVID-19 pandemic calamity, the world is conscious of life-saving drugs' criticality developed and rapidly brought to market. The drugs being brought to market result from a close partnership with the sponsor company, which works with a clinical research organization (CRO) that manages the clinical trials. Several drugs go through various development phases from the concept to the commercialization stage. A suitable CRO is deemed invaluable in the situation, especially to a sponsor company in its search to bring a novel drug to market. A poor performing CRO can cause a new drug's regulatory approval to be denied or delayed. As SARS-CoV-2 persists in its spread globally, several players are dedicated to arranging support for uncovering an active immune and prophylactic plan to back the biotech, pharmaceutical, and academic groups in advancing anti-viral medication and vaccines against SARS-CoV-2.

Preclinical CRO Market Trends


Growth In Outsourcing Of Non-Core Function

The need to focus on core functions is projected to lead to an increased offloading of non-essential activities, thus boosting the preclinical CRO market growth.

Enhanced Abilities Of Preclinical Cros To Offer Additional Value-Added Services

The diversification and advancement of the additional value-added services is predicted to give the preclinical CRO market revenue a boost in the future.

Surging Number Of Drugs In The Preclinical Phase

The burgeoning volume of products in the preclinical testing phase is predicted to enhance the forthcoming period's preclinical CRO market size.

Economies Of Production And Scale

The ability to easily reach economies of production and scale is estimated to work out in favor of the market of preclinical CRO in the impending period.


Opportunity For Medical Device Companies To Outsource Preclinical Trials

The demand for medical device testing has risen incrementally over the past few years, which is foreseen to be outsourced to preclinical CROs, thus motivating the global market in recent years.


Scarcity Of Labour And High Labour Cost

The shortage of labor that is specialized related to requirements to the sector is estimated to create a restriction on the overall growth.

Structural Changes In The Industry

The changes in the market's overall structure are estimated to reduce the momentum for the market of preclinical CRO development in the near future.

Preclinical CRO Market Segment Insights

Preclinical CRO Service Insights

The toxicology testing segment is anticipated to spearhead the market of preclinical CRO and record a considerable CAGR during the forecast period. Growing demand for new drugs and chemicals and dynamic development in the biopharmaceutical and pharmaceutical sectors is anticipated to drive the preclinical CRO market growth. The bioanalysis and drug metabolism and pharmacokinetics (DMPK) studies segment is anticipated to show a peak CAGR by 2032.

Preclinical CRO Application Insights

Oncology is likely to appear as the leading segment in the forthcoming period.

Preclinical CRO End-User Insights

The pharmaceutical and biopharmaceutical industries segment is foreseen to create an impetus for market growth of preclinical CRO in the future.

Preclinical CRO Market Regional Analysis

Americas To Exert Dominance On Global Market

The Americas regional market for preclinical CROs was the preclinical CRO's prime market in 2018 and is expected to continue its strong influence throughout the review period.

European Regional Market Shows Market

The European regional market reported a vital stake and is projected to be the second-largest market during the forecast period. The snowballing outsourcing undertakings in Europe are driving the market development of the preclinical CRO region's. Germany reported for the principal market portion of 24.7% in 2018, and the national-level market is anticipated to touch a CAGR of 6.69% throughout the forecast period.

Preclinical CRO Market Competitive Landscape

The foremost players in the market of Preclinical CRO are

  • IQVIA (U.S.),

  • PAREXEL International Corporation (U.S.),

  • Envigo (U.S.),

  • Charles River (U.S.),

  • Eurofins Scientific (Luxembourg),

  • ICON PLC (Dublin),

  • PRA Health Sciences (U.S.),

  • Medpace (U.S.),

  • Laboratory Corporation of America Holdings (U.S.),

  • Pharmaceutical Product Development, LLC (U.S.),

  • WuXi AppTec (China)

  • D. Biosciences (U.S.)

Recent Developments

Jan 2021 Charles River Labs, a major CRO specializing in preclinical research programs, has inked a new invention pact as the role of a sequence of deals over the previous years. Charles River bought antibody discovery company disseminated Bio for up to USD104 million; the companies declared recently, a figure that includes USD 83 million in forthright cash. The other USD 21 million in the deal is set aside for future performance payments. With the procurement, Charles River hopes to achieve the goal of removing an additional year from our clients' early-stage development timelines.

Dec 2020 Mountain Valley MD Holdings Inc. has filed for a fast-tracked appraisal of its macrocyclic lactone solubilization patent with the United States Patent and Trademark Office (USPTO). Mountain Valley MD beforehand established its capability to prepare the anti-parasitic drug Ivermectin very water-soluble without using organic solvents, refining its water solubility by closely 5,000 times it had accomplished its preliminary safety and improved effectiveness in preclinical authentication with the foremost third-party preclinical CRO.  

Jan 2021 Editas Medicine, Inca leading genome editing firm, revealed the U.S. Food and Drug Administration (FDA) had cleared the beginning of the safety stage of the Company's EDIT-301 clinical trial, and the company can begin medicating patients. The company must develop and propose to the FDA an improved potency assay before registering in the RUBY trial's effectiveness stage. The firm has recognized a principal researcher and involved a Clinical Research Organization (CRO).

Jan 2021 Explora BioLabs,  a preclinical vivarium, husbandry, and research space supplier, will present its first East Coast facility in Boston in mid-2021.  The novel Explora facility will deliver the Boston biotech sector with an entirely administered, off-site research facility with an approach to crucial adjacent preclinical services and professional staff to support client research. The area will allow researchers to concentrate on their work while Explora handles all of the in vivo running, logistics, and compliance necessities.

Sep 2020 Viva Biotech is investing down USD 80 million to purchase preclinical contract research organization SYNthesis and lift its outsourcing business. Hong Kong-based SYNthesis is a preclinical small-molecule drug discovery service contract organization offering synthetic chemistry and pharmaceutical chemistry services to its clients. It will now come under Shanghai-based Viva Biotech's patronage, an integrated drug discovery platform dedicated to preclinical-stage innovative drug development, covering the full range of our customers' requirements for early-stage drug discovery.

Preclinical CRO Market Segmentation

Preclinical CRO Service Outlook

  • Toxicology Testing

  • Bioanalysis and Drug Metabolism and Pharmacokinetics (DMPK) Studies

  • Others

Preclinical CRO Application Outlook

  • Oncology

  • Central Nervous System (CNS) Disorders

  • Cardiovascular Diseases

  • Immunological Disorders

  • Respiratory Diseases

  • Infectious Diseases

  • Diabetes

  • Others

Preclinical CRO End-User Outlook

  • Pharmaceutical and Biopharmaceutical Industries

  • Medical Device Companies

  • Academic Institutes

Report Attribute/Metric Details
  Market Size   USD 10.3 Billion
  CAGR   7.2%
  Base Year   2023
  Forecast Period   2024-2032
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Service, Application, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   IQVIA (US), PAREXEL International Corporation (US), Envigo (US), Charles River (US), Eurofins Scientific (Luxembourg), ICON PLC (Dublin), PRA Health Sciences (US), Medpace (US), Laboratory Corporation of America Holdings (US), Pharmaceutical Product Development, LLC (US), WuXi AppTec (China), MD Biosciences (US)
  Key Market Opportunities   Opportunity For Medical Device Companies To Outsource Preclinical Trials
  Key Market Drivers ·  Growth In Outsourcing Of Non-Core Function·  Enhanced Abilities Of Preclinical Cros To Offer Additional Value-Added Services·  Surging Number Of Drugs In The Preclinical Phase·  Economies Of Production And Scale

Frequently Asked Questions (FAQ) :

Service and Application are leading segment

Preclinical CRO Market is expected to reach a valuation of USD 10.3 billion by 2032.

Preclinical CRO Market is expected to exhibit a strong 7.2% CAGR over the forecast period.

The growing demand for outsourcing non-core functions in the pharmaceutical industry is the major driver for the global preclinical CRO market.

The Americas hold the dominant share in the global preclinical CRO market, accounting for more than 40% of the market in 2018.

Toxicology testing holds the highest share in the global preclinical CRO market.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.